ReviewDrug design, development and therapy2018

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.

Stephanie Vairy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.